Merck & Co., Inc. (MRK) Announces Update on Phase 3 KEYNOTE-905 Trial

Merck & Co., Inc. (NYSE:MRK) is included in our list of the 10 Most Undervalued Value Stocks to Buy Now.

On August 12, 2025, Merck & Co., Inc. (NYSE:MRK) announced an update regarding its Phase 3 KEYNOTE-905 trial. According to the update, the trial met its primary and key secondary endpoints in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy.

The study revealed improved event-free survival, overall survival, and pathologic complete response rates compared to surgery alone. The improved outcome was a result of giving patients KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin-ejfv) medicines before and after surgery.

The trial, carried out in collaboration with Pfizer and Astellas, marks the first systemic treatment that enhances survival rates in this patient group. Furthermore, no new side effects were observed.

Operating through its Pharmaceutical and Animal Health segments, Merck & Co., Inc. (NYSE:MRK) leads as a healthcare company worldwide. It is included in our list of the most undervalued value stocks to buy.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 13 Best Oil Refinery Stocks to Buy Right Now and 7 Best Potash Stocks to Buy According to Analysts.

Disclosure: None.